Clinical Trials Logo

Clinical Trial Summary

Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it with the individual drugs


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01227603
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date November 2010
Completion date July 2011

See also
  Status Clinical Trial Phase
Completed NCT06448962 - Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 Phase 3
Completed NCT03258489 - Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients N/A
Terminated NCT02245230 - Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension Phase 1
Completed NCT05631990 - A Study to Evaluate the Efficacy and Safety of AD-209 Phase 2
Completed NCT02466490 - Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension Phase 3
Completed NCT01303783 - Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension Phase 2
Completed NCT01350609 - Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed Phase 1
Not yet recruiting NCT04332562 - The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension N/A